Verrica Pharmaceuticals Inc (VRCA)
0.8335
-0.03
(-3.45%)
USD |
NASDAQ |
Nov 15, 16:00
0.8338
0.00 (0.00%)
After-Hours: 20:00
Verrica Pharmaceuticals Research and Development Expense (TTM): 15.99M for Sept. 30, 2024
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| September 30, 2024 | 15.99M |
| June 30, 2024 | 20.10M |
| March 31, 2024 | 22.50M |
| December 31, 2023 | 20.29M |
| September 30, 2023 | 18.00M |
| June 30, 2023 | 14.27M |
| March 31, 2023 | 12.49M |
| December 31, 2022 | 12.20M |
| September 30, 2022 | 12.52M |
| June 30, 2022 | 13.51M |
| March 31, 2022 | 13.01M |
| December 31, 2021 | 15.93M |
| September 30, 2021 | 14.84M |
| June 30, 2021 | 16.07M |
| Date | Value |
|---|---|
| March 31, 2021 | 16.14M |
| December 31, 2020 | 15.67M |
| September 30, 2020 | 17.37M |
| June 30, 2020 | 15.43M |
| March 31, 2020 | 15.84M |
| December 31, 2019 | 15.44M |
| September 30, 2019 | 16.38M |
| June 30, 2019 | 16.80M |
| March 31, 2019 | 16.39M |
| December 31, 2018 | 12.83M |
| September 30, 2018 | 9.027M |
| June 30, 2018 | 6.68M |
| March 31, 2018 | 4.142M |
| December 31, 2017 | 3.73M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
12.20M
Minimum
Dec 2022
22.50M
Maximum
Mar 2024
15.88M
Average
15.76M
Median
Research and Development Expense (TTM) Benchmarks
| Biomarin Pharmaceutical Inc | 779.92M |
| Elite Pharmaceuticals Inc | 7.903M |
| Eagle Pharmaceuticals Inc | 35.65M |
| TELA Bio Inc | 9.469M |
| Terns Pharmaceuticals Inc | 69.23M |